Compare Novo Nordisk A/S (NVO) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Twilio Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Twilio Inc trades at $195.99 (market cap $31.15B). The key difference: Novo Nordisk A/S is far larger — about 7.1× Twilio Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| NVO | TWLO | |
|---|---|---|
Market Cap | $220.53B | $31.15B |
Sector | Health | Technology |
52-Week High | $71.70 | $236.64 |
52-Week Low | $35.29 | $92.44 |
Enterprise Value | $239.49B | $29.87B |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
